Compare KEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | EVO |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | Singapore | Germany |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | KEN | EVO |
|---|---|---|
| Price | $65.16 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 12.1K | ★ 269.8K |
| Earning Date | 12-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | $803,304,000.00 | ★ $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.80 |
| P/E Ratio | $7.14 | ★ N/A |
| Revenue Growth | ★ 8.15 | N/A |
| 52 Week Low | $27.10 | $2.84 |
| 52 Week High | $66.36 | $5.10 |
| Indicator | KEN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 76.52 | 51.23 |
| Support Level | $60.35 | $2.87 |
| Resistance Level | $62.68 | $3.05 |
| Average True Range (ATR) | 1.24 | 0.09 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 87.76 | 75.68 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.